ACE2 and COVID-19: A high‐throughput virtual screening following with followed by molecular dynamics simulation studies identified ledipasvir, vancomycin from an US FDA‐approved drug library; drugs were screened for their ability to, through interfering block the binding of S protein to ACE2 or CD147, which are potential candidates for further investigation as possible treatments of COVID‐19 and novel drug development.226